Kringle Pharma, the Osaka biotech developing drugs from recombinant human HGF protein, has narrowed the operating loss it expects for the year to September 2026. Its board raised the sales forecast 33.1%, to ¥442mn from ¥332mn, and cut the projected operating loss to ¥800mn from ¥1,018mn. Ordinary-loss guidance improved to ¥796mn from ¥1,018mn, and the net-loss forecast narrowed to ¥799mn from ¥1,020mn, trimming the per-share loss to ¥103.52 from ¥139.85.
| Metric | Previous forecast | Revised forecast |
|---|---|---|
| Net sales | ¥332mn | ¥442mn |
| Operating loss | ¥1.02bn loss | ¥800mn loss |
| Ordinary loss | ¥1.02bn loss | ¥796mn loss |
| Net loss | ¥1.02bn loss | ¥799mn loss |
| Loss per share | ¥139.85 | ¥103.52 |
The sales increase is almost entirely a single contract fee. On the same day, Kringle Pharma signed a definitive agreement giving Maruishi Pharmaceutical exclusive rights to sell and promote KP-100LI, an experimental treatment for vocal-fold scarring built on recombinant human HGF protein, in Japan. Maruishi will act as sole distributor while Kringle Pharma keeps development, manufacturing approval and supply. The ¥100mn upfront payment is due to be recorded as revenue for the year to September 2026; milestone payments and royalty rates are kept confidential under the contract.
The operating-loss forecast improved by ¥218mn in total, and the licensing fee explains only part of that. About ¥108mn of spending on commercial-formulation development for the same drug has simply shifted into next fiscal year, not disappeared, and that timing shift adds roughly as much to the narrower loss as the ¥110mn increase in sales guidance itself.
KP-100LI has not been approved for sale. It remains in a placebo-controlled Phase 3 trial; patient enrollment finished in January 2026, and Kringle Pharma expects topline results only in 2027. The Maruishi deal extends a partnership dating to 2020, when the two companies signed a similar license for a spinal-cord-injury drug and Maruishi took a 1.16% stake in Kringle Pharma that it still holds. The companies say they are still discussing whether Maruishi will invest further in Kringle Pharma.